Year |
Citation |
Score |
2023 |
Nguyen H, Schubert KE, Chang E, Nie Y, Pohling C, Van Buskirk SL, Yamamoto V, Zeng Y, Schulte RW, Patel CB. Electric field distributions in realistic 3D rat head models during alternating electric field (AEF) therapy: a computational study. Physics in Medicine and Biology. PMID 37703902 DOI: 10.1088/1361-6560/acf98d |
0.454 |
|
2022 |
Pohling C, Nguyen H, Chang E, Schubert KE, Nie Y, Bashkirov V, Yamamoto V, Zeng Y, Stupp R, Schulte RW, Patel CB. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. Bioelectrochemistry (Amsterdam, Netherlands). 149: 108287. PMID 36306728 DOI: 10.1016/j.bioelechem.2022.108287 |
0.497 |
|
2022 |
Arami H, Kananian S, Khalifehzadeh L, Patel CB, Chang E, Tanabe Y, Zeng Y, Madsen SJ, Mandella MJ, Natarajan A, Peterson EE, Sinclair R, Poon ASY, Gambhir SS. Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostars. Nature Nanotechnology. PMID 35995855 DOI: 10.1038/s41565-022-01189-y |
0.397 |
|
2021 |
Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, Bomzon Z, Patel CB. Permeabilizing Cell Membranes with Electric Fields. Cancers. 13. PMID 34068775 DOI: 10.3390/cancers13092283 |
0.493 |
|
2021 |
Patel C, Beinat C, Xie Y, Chang E, Gambhir S. BIMG-16. TRACKING TTFIELDS-INDUCED ALTERATIONS IN GLIOBLASTOMA METABOLISM WITH [18F]DASA-23, A NON-INVASIVE PROBE OF PYRUVATE KINASE M2 (PKM2) Neuro-Oncology Advances. 3: i4-i4. DOI: 10.1093/noajnl/vdab024.015 |
0.467 |
|
2020 |
Patel CB, Beinat C, Xie Y, Chang E, Gambhir SS. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. Neoplasia (New York, N.Y.). 23: 58-67. PMID 33221711 DOI: 10.1016/j.neo.2020.11.003 |
0.475 |
|
2020 |
Chang E, Patel C, Young C, Flores T, Zeng Y, Joubert L, Arami H, Natarajan A, Sinclair R, Gambhir S. CSIG-14. COMBINING THE GLIOBLASTOMA CELL MEMBRANE-PERMEABILIZING EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) WITH WITHAFERIN A (AND OTHER) CHEMOTHERAPY Neuro-Oncology. 22: ii30-ii30. DOI: 10.1093/neuonc/noaa215.126 |
0.357 |
|
2019 |
Patel CB, Beinat C, Xie Y, Chang E, Gambhir SS. Abstract 5271: Molecular imaging of pyruvate kinase M2 (PKM2) with [18F]DASA-23 detects temozolomide- and tumor treating fields (TTFields)-induced changes in glycolysis in glioblastoma Cancer Research. 79: 5271-5271. DOI: 10.1158/1538-7445.Am2019-5271 |
0.41 |
|
2019 |
Chang E, Patel C, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS. Abstract 250: Tumor treating fields increases membrane permeability in glioblastoma cells Cancer Research. 79: 250-250. DOI: 10.1158/1538-7445.Am2019-250 |
0.421 |
|
2019 |
Chang E, Patel C, Beinat C, Young C, Flores T, Zeng Y, Joubert L, Arami H, Natarajan A, Sinclair R, Gambhir S. EXTH-53. TUMOR TREATING FIELDS LEADS TO CHANGES IN MEMBRANE PERMEABILITY AND INCREASED PENETRATION BY ANTI-GLIOMA DRUGS Neuro-Oncology. 21: vi93-vi93. DOI: 10.1093/Neuonc/Noz175.384 |
0.353 |
|
2018 |
Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discovery. 4: 113. PMID 30534421 DOI: 10.1038/S41420-018-0130-X |
0.499 |
|
2018 |
Chang E, Patel C, Pohling C, Beygui N, Ha DH, Gambhir SS. Abstract 5828: Withaferin A and tumor treating fields synergistically inhibit glioma proliferation Cancer Research. 78: 5828-5828. DOI: 10.1158/1538-7445.Am2018-5828 |
0.361 |
|
2017 |
Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, Gambhir SS. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. Journal of Neuro-Oncology. PMID 28681243 DOI: 10.1007/S11060-017-2534-5 |
0.486 |
|
2017 |
Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, Gambhir SS. DDIS-15. SYNERGISTIC INHIBITION OF GLIOMA CELL PROLIFERATION BY WITHAFERIN A AND TUMOR TREATING FIELDS Neuro-Oncology. 19: vi61-vi62. DOI: 10.1093/neuonc/nox168.250 |
0.311 |
|
2012 |
Xu Y, Chang E, Liu H, Jiang H, Gambhir SS, Cheng Z. Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 312-7. PMID 22241909 DOI: 10.2967/Jnumed.111.094623 |
0.326 |
|
2011 |
Chang E, Liu S(, Berhoerster K, Ellinghaus P, Liu S(, Gekeler V, Cheng Z, Berndorff D, Gambhir SS. Abstract LB-147: 18F-FAZA-PET as a pharmacodynamic biomarker of anti-tumor activity for the novel HIF-1α pathway inhibitor BAY 87–2243 in preclinical tumor models Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-147 |
0.319 |
|
Show low-probability matches. |